Novartis Sponsored Session: Which Symptoms and Impacts Matter to Patients who Suffered Sepsis-Associated Acute Kidney Injury? Preliminary Results from a Patient Experience Study
Description:
This session is part of Sepsis Alliance Summit 2025.
The session summarizes early findings from a patient experience study on Sepsis-Associated Acute Kidney Injury (SA-AKI). The presentation details the study’s patient-centric methodology, including interviews with individuals from the U.S. and Germany, aimed at eliciting symptoms and life impacts of SA-AKI. Key burdensome symptoms identified include cognitive decline, kidney dysfunction, and physical fatigue, while impacts span emotional distress, sleep issues, and financial strain. The results of this research, once finalized, aim to improve awareness of the disease, inform clinical trials and clinical practice in SA-AKI.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session Supporter:
Sepsis Alliance gratefully acknowledges the support of this session provided by Novartis.
Simon Messner, PhD
Director, Patient Engagement Scientific Excellence
Novartis
Simon Messner, PhD, has over 15 years of experience in the biotech and pharmaceutical industry. For the past three years, he has focused on patient engagement activities at Novartis, where he is passionate about embedding Patient-Focused Drug Development practices across multiple assets within the development organization.